NEOL needs some research

Discussion in 'Stocks' started by topdown, Feb 23, 2007.

  1. topdown

    topdown

    This thing traded in the $20's a few years ago. Severely beaten down and has been in the $1.75 range since December. Major breakout today - up 25% on HUGE volume. I couldn't find any news at first glance, but it looks like it's worth looking into.

    Business summary:

    NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of cancer in the United States. Its product candidates comprise Cintredekin besudotox, a Phase III clinical trial product for the treatment of brain cancer; LE-SN38, a Phase II clinical trial product for the treatment of colorectal cancer and other solid tumors; LEP-ETU, a Phase II clinical trial product for the treatment of breast cancer, lung cancer, ovarian cancer, and other solid tumors; and LErafAON, a Phase I clinical trial product for the treatment of cancer. The company has a license agreement with Nippon Kayaku Co., Ltd., for the development and commercialization of Cintredekin besudotox in Japan. NeoPharm was incorporated in 1990 under the name OncoMed, Inc. and changed its name to NeoPharm, Inc. in 1995. NeoPharm is headquartered in Waukegan, Illinois.